Ghaith Abu-Zeinah, MD, Weill Cornell Medicine, New York, NY, discusses the results from a meta-analysis exploring the use of cytoreductive agents in younger patients with polycythemia vera (PV). The meta-analysis challenged previous ideas that cytoreductive agents caused extreme toxicity in PV patients younger than 60 years old, with data from 14 studies showing low toxicity and annual discontinuation rates for both interferon and hydroxyurea. Dr Abu-Zeinah emphasizes that this evidence supports the use of cytoreductive therapy, especially interferon, for the treatment of younger patients with PV, stating that he believes there should be a paradigm shift in clinical practice. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
